Objective: To provide guidance to rheumatology providers on the use of COVID-19 vaccines for patients with rheumatic and musculoskeletal diseases (RMDs).
Methods: A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious diseases specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID-19 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9-point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings.
Results: Despite a paucity of direct evidence, statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID-19 vaccines, including supplemental/booster dosing, in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination.
Conclusion: These guidance statements are intended to provide direction to rheumatology health care providers on how to best use COVID-19 vaccines and to facilitate implementation of vaccination strategies for RMD patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878068 | PMC |
| http://dx.doi.org/10.1002/art.42372 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Poison, lies, war: A mixed methods content analysis of posts about COVID-19 vaccination on Gab Social.
Hum Vaccin Immunother
December 2025
Communication Department, California State Polytechnic University, Pomona, CA, USA.
Recent surges in COVID-19 cases demonstrate the unabated transmissibility of this disease. Despite the ongoing threat of contagion, however, uptake of the COVID-19 vaccines, especially as booster doses, remains suboptimal among eligible adults and children in the United States, as reported by the World Health Organization (WHO). Public attitudes toward these vaccines remain balkanized, with some groups harboring ambivalence or even opposition to receiving inoculation.
View Article and Find Full Text PDFMVA-based SARS-CoV-2 vaccine candidates encoding different spike protein conformations induce distinct early transcriptional responses which may impact subsequent adaptive immunity.
Front Immunol
January 2025
Institute for Infection Research and Vaccine Development (IIRVD), Center for Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Introduction: Vaccine platforms such as viral vectors and mRNA can accelerate vaccine development in response to newly emerging pathogens, as demonstrated during the COVID-19 pandemic. However, the differential effects of platform and antigen insert on vaccine immunogenicity remain incompletely understood. Innate immune responses induced by viral vector vaccines are suggested to have an adjuvant effect for subsequent adaptive immunity.
View Article and Find Full Text PDFWillingness to receive COVID-19 vaccine and associated factors among teachers in Dambi Dollo, Ethiopia: a cross-sectional study.
BMC Public Health
January 2025
Department of Nursing, College of Health Sciences, Salale University, Fiche, Ethiopia.
Background: Teachers play important roles in influencing vaccine uptake decisions and should serve as examples for their students by willingly getting vaccinated. Given the low vaccination rates in this area, it is crucial to explore teachers' willingness to get vaccinated and emphasize their role in promoting vaccine acceptance.
Objective: The main objective of this study was to assess the willingness of teachers to receive the COVID-19 vaccine and its associated factors in Dambi Dollo town.
Modeling COVID-19 dynamics in the Basque Country: characterizing population immunity profile from 2020 to 2022.
BMC Infect Dis
January 2025
Basque Center for Applied Mathematics, Bilbao, Bizkaia, Spain.
Background: COVID-19, caused by SARS-CoV-2, has spread globally, presenting a significant public health challenge. Vaccination has played a critical role in reducing severe disease and deaths. However, the waning of immunity after vaccination and the emergence of immune-escape variants require the continuation of vaccination efforts, including booster doses, to maintain population immunity.
View Article and Find Full Text PDFDevelopment of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screening.
Nat Commun
January 2025
Department of Chemistry, Columbia University, New York, NY, USA.
Variants of SARS-CoV-2 have continued to emerge across the world and cause hundreds of deaths each week. Due to the limited efficacy of vaccines against SARS-CoV-2 and resistance to current therapies, additional anti-viral therapeutics with pan-coronavirus activity are of high interest. Here, we screen 2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!